Felvizumab

Felvizumab is a humanized monoclonal antibody against respiratory syncytial virus.[1]

Felvizumab
Monoclonal antibody
Type	Whole antibody
Source	Humanized (from mouse)
Target	RSV
Clinical data
ATC code	none
Identifiers
CAS Number	167747-20-8^N
ChemSpider	none
KEGG	D04136^Y
^NY (what is this?) (verify)

References

WHO Drug Information

Monoclonal antibodies for infectious disease and toxins

Human	Efungumab^†

Human	Ansuvimab Atoltivimab (+maftivimab/odesivimab) Bamlanivimab^† Casirivimab^† (+imdevimab)^† Diridavumab^§ Exbivirumab^§ Foravirumab^§ Imdevimab^† Libivirumab^§ Maftivimab Odesivimab Rafivirumab^§ Regavirumab^§ Sevirumab^† Suptavumab Tuvirumab^§
Chimeric	Cosfroviximab Larcaviximab Porgaviximab
Humanized	Felvizumab^§ Lenvervimab^† Motavizumab^† Palivizumab Suvizumab^§

Human	Nebacumab Panobacumab^§ Raxibacumab
Mouse	Edobacomab^§
Chimeric	Pagibaximab^†
Humanized	Tefibazumab^†

Human	Actoxumab^§ Bezlotoxumab Suvratoxumab
Chimeric	Obiltoxaximab
Humanized	Urtoxazumab^§

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.